Epidemiology and cost of treatment of genital warts in Spain

European Journal of Public Health

Volumn 19, Issue 1, 2009, Pages 106-110

  Castellsagué, Xavier ^a   Cohet, Catherine ^b   Puig Tintoré, Luis M ^c   Acebes, Luis Olmos ^d   Salinas, Jesus ^e   Martin, Maria San ^f   Breitscheidel, Lusine ^g   Rémy, Vanessa ^b  

^a CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^b SANOFI PASTEUR   (France)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f Sanofi Pasteur MSD   (Spain)

^g Kendle   (Germany)

Author keywords

Costs; Epidemiology; Genital warts; Human papillomavirus; Spain

Indexed keywords

IMIQUIMOD; PODOPHYLLOTOXIN; UNCLASSIFIED DRUG; WARTEC;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CALCULATION; COLPOSCOPY; CONDYLOMA ACUMINATUM; COST OF ILLNESS; COST UTILITY ANALYSIS; CRYOTHERAPY; FEMALE; HOSPITALIZATION COST; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONEY; OBSERVATIONAL STUDY; PAPANICOLAOU TEST; PREVALENCE; PRIORITY JOURNAL; RECURRENT INFECTION; RETROSPECTIVE STUDY; SPAIN;

ADOLESCENT; ADULT; CONDYLOMATA ACUMINATA; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 6; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPAIN; YOUNG ADULT;

EID: 59449097418     PISSN: 11011262     EISSN: 1464360X     Source Type: Journal    
DOI: 10.1093/eurpub/ckn127     Document Type: Article

References (22)

1. von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001;11:598-603.
2. Lacey CJN, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006;24:S3/35-S3/41.
3. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8.
4. Fenton KA, Lowndes CM. Recent trends in the epidemiology of sexually transmitted infections in the European Union. Sex Trans Infect 2004;80:255-63.
5. UK Collaborative Group for HIV and STI Surveillance. A Complex Picture. HIV and Other Sexually Transmitted Infections in the United Kingdom: 2006. London: Health Protection Agency, 2006. Available at: http://www.hpa.org.uk/ publications/2006/hiv-sti-2006/default.htm (accessed 15 January 2008).
6. Scheinfeld N, Lehman DS. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J 2006;12:5.
7. van der Meijden WI, Notowicz A, Blog FB, Langley PC. A retrospective analysis of costs and patterns of treatment for external genital warts in The Netherlands. Clin Ther 2002;24:183-96.
8. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003;36:1397-403.
9. Langley PC, White DJ, Drake SM. The costs of treating external genital warts in England and Wales: a treatment pattern analysis. Int J STD AIDS 2004;15:501-8.
10. Monsonégo J, Breugelmans JG, Bouée S, Lafuma A, Bénard S, Rémy V. Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France. Gynécol Obstétr Fert 2007;35:107-13.
11. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Eng J Med 2007;356:1915-27.
12. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Eng J Med 2007;356:1928-43.
13. Lukasiewicz E, Aractingi S, Flahault A. Incidence and management of condylomata acuminata by French general physicians. Annales de dermatologie et de vénéréologie 2002;129:991-6.
14. Brown RE, Breugelmans JG, Theodoratou D, Bénard S. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006;22:663-70.
15. Hillemanns P, Breugelmans JG, Gieseking F, et al. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis 2008;8:76.
16. Epstein M. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Safety 2005;14:589-95.
17. Instituto Nacional de Estatistica, Base de datos INEbase. Available at: http://www.ine.es/inebmenu/indice.htm (accessed 11 January 2008).
18. de Sanjose S, Cortés X, Méndez C, et al. Age at sexual initiation and number of sexual partners in the female Spanish population. Results from the AFRODITA survey. Eur J Obstet Gynecol Reprod Biol 2008;140:234-40.
19. Puig-Tintoré LM, Castellsagué X, Torné A, et al. Coverage and factors associated with cervical cancer screening: results from the AFRODITA study, a population-based survey in Spain. J Low Genit Tract Dis 2008;12:82-9.
20. Health Protection Agency. Centre for Infections. Diagnoses and rates of selected STIs seen at GUM clinics: 2001-2005. National & Regional Level Summary Tables, 2006. Available at: http://www.hpa.org.uk/infections//topics-az/ hiv-and-sti/epidemiology/2005data/Selected-sti-region-sex-age-grp-2001-2005-AR. pdf (accessed 15 January 2008).
21. Health Protection Agency. Centre for Infections. Diagnoses and rates of selected STIs seen at GUM clinics in England: 2001-2005. Strategic Health Authority Level Summary Tables, 2006. Available at: http://www.hpa.org.uk/ infections//topics-az/hiv-and-sti/epidemiology/2005datatables/ Selected-sti-sha-sex-age-grp-2001-2005.pdf (accessed 15 January 2008).
22. Langley PC, Tyring SK, Smith MH. The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts. Am J Manag Care 1999;5:69-77.